Laxmi Organic is that ambitious topper who keeps promising to “double revenue and triple EBITDA by 2028,” but whose Q1 FY26 profit just shrank 38%. The company sells solvents (ethyl acetate), specialty chemicals (diketene, fluoros), and dreams of global leadership. Current P/E: 55. Current ROE: 6%. Basically, champagne valuation for chai profits.
2. Introduction
Born in 1989, Laxmi Organic Industries (LXCHEM) has morphed from a humble acetates producer into a mid-tier specialty chemicals aspirant with offices in 11 Indian cities and sales in 50+ countries.
They operate in two buckets:
Essentials: Commodity-like solvents and acetates. Cheap, large-volume stuff.
Specialties: Higher-margin diketene derivatives, esters, fluoros. Used by pharma, agro, coatings, pigments, and electronics. Basically, the “fancy” side of chemistry.
The problem? Essentials give volume, Specialties give hope. EBITDA split (9MFY25) already tilts 68% toward Specialties, but profits remain elusive. With a ₹1,100 Cr capex program running till FY28, management wants to play in the big league with Navin Fluorine, Deepak Nitrite, and Gujarat Fluoro.
But the stock’s last one-year return is –32%. Investors are asking: “Beta, tu karega ya bas bolega?”
3. Business Model – WTF Do They Even Do?
Let’s break this down for our lazy investor friend:
Essentials (solvents, acetates, ethanol): Cheap, high-volume. End users = pharma excipients, packaging films, paint thinners. Think of this as “bread and butter” but with razor-thin margins.
Specialties (diketene, fluoros, ketenes): Higher-value intermediates for pharma APIs, agrochemicals, pigments. This is where the real margins and bragging rights come from.
Fluorospecialties: Through Yellowstone Fine Chemicals (merger pending), Laxmi is entering the Holy Grail of chemicals—fluoro. Used in green refrigerants, pharma, semiconductors. Everyone’s chasing it.
Customer profile: 650+ active customers, concentration falling (top 10 down from 41% of sales in FY22 to 25% in 9MFY25). They’re trying to be less dependent on any one sugar daddy.
Exports are diversified: 33% Americas, 21% Europe, 17% Middle East, and the rest scattered. Pharma and packaging dominate (together ~59% of revenue).
So in short: bulk solvents keep the lights on, while the dream is to build a global specialty giant.
4. Financials Overview
Metric
Latest Qtr (Q1 FY26)
YoY Qtr (Q1 FY25)
Prev Qtr (Q4 FY25)
YoY %
QoQ %
Revenue (₹ Cr)
693
718
710
-3.5%
-2.4%
EBITDA (₹ Cr)
31
71
59
-56%
-47%
PAT (₹ Cr)
21.4
34
22
-37.7%
-2.7%
EPS (₹)
0.77
1.24
0.79
-37.7%
-2.5%
Commentary: Quarterly EPS at ₹0.77 annualises to ₹3.1. At CMP ₹202, that’s a P/E ~65. Essentials are boring, Specialties are exciting, but investors are paying Netflix rates for Doordarshan content.
